Varghese Leila N, Defour Jean-Philippe, Pecquet Christian, Constantinescu Stefan N
Ludwig Institute for Cancer Research, Brussels Branch, Brussels, Belgium.
SIGN Pole, de Duve Institute, Université catholique de Louvain, Brussels, Belgium.
Front Endocrinol (Lausanne). 2017 Mar 31;8:59. doi: 10.3389/fendo.2017.00059. eCollection 2017.
A well-functioning hematopoietic system requires a certain robustness and flexibility to maintain appropriate quantities of functional mature blood cells, such as red blood cells and platelets. This review focuses on the cytokine receptor that plays a significant role in thrombopoiesis: the receptor for thrombopoietin (TPO-R; also known as MPL). Here, we survey the work to date to understand how this receptor functions at a molecular level throughout its lifecycle, from traffic to the cell surface, dimerization and binding cognate cytokine its extracellular domain, through to its subsequent activation of associated Janus kinases and initiation of downstream signaling pathways, as well as the regulation of these processes. Atomic level resolution structures of TPO-R have remained elusive. The identification of disease-causing mutations in the receptor has, however, offered some insight into structure and function relationships, as has artificial means of receptor activation, through TPO mimetics, transmembrane-targeting receptor agonists, and engineering in dimerization domains. More recently, a novel activation mechanism was identified whereby mutated forms of calreticulin form complexes with TPO-R its extracellular N-glycosylated domain. Such complexes traffic pathologically in the cell and persistently activate JAK2, downstream signal transducers and activators of transcription (STATs), and other pathways. This pathologic TPO-R activation is associated with a large fraction of human myeloproliferative neoplasms.
一个功能良好的造血系统需要一定的稳健性和灵活性,以维持适量的功能性成熟血细胞,如红细胞和血小板。本综述聚焦于在血小板生成中起重要作用的细胞因子受体:血小板生成素受体(TPO-R;也称为MPL)。在这里,我们综述了迄今为止的研究工作,以了解该受体在其整个生命周期中如何在分子水平上发挥作用,从转运到细胞表面、二聚化以及与细胞外结构域的同源细胞因子结合,到随后激活相关的Janus激酶并启动下游信号通路,以及这些过程的调控。TPO-R的原子水平分辨率结构仍然难以确定。然而,受体中致病突变的鉴定为结构与功能关系提供了一些见解,通过血小板生成素模拟物、跨膜靶向受体激动剂以及二聚化结构域工程等人工激活受体的方法也提供了相关见解。最近,一种新的激活机制被发现,即钙网蛋白的突变形式与TPO-R的细胞外N-糖基化结构域形成复合物。这种复合物在细胞内发生病理性转运,并持续激活JAK2、下游信号转导和转录激活因子(STATs)以及其他通路。这种病理性TPO-R激活与很大一部分人类骨髓增殖性肿瘤相关。